Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Rewind, pre-market doesn’t count. However, USPS contract could blow the doors off your RIDE.
And at the finish line it looks like RIDE wins by just a bumper. Hopefully we start getting new highs.
Yep, what’s up is the question.
Let’s see if something starts brewing. Took a small position today, figured it couldn’t hurt with the sp this low.
You know a stock is dead when Clay Trader shows up twice on the same page 30 days later. News IS coming, when they announce a reverse split. JMO
Glad to hear your trading this thing and not just holding a long position. I’ll text again when I see low .90’s. I really hope that anyone long ends up proving me wrong about low 90’s.
I had high hopes for this company. Followed Cann from the very beginning. I hope they can turn things around, I truly believed in them. When Robert F. stepped down from ceo I started having my doubts. Will always keep an eye on this company and pray things get better.
R U still excited about this stock? Did you average down or still holding around a 1.36? Just wait till it starts trading in fractions of a penny, then it get even better. Not saying it will but it has in the past. GL
Wow another patent added to the pile. Hope they don’t do another price offering like they did the day after getting their U.S. patent. Proceed with caution. Hope y’all can make a lot of money so your hard-earned money doesn’t end up in their pocket like mine did.
Except this as a gift today, trade cautiously.
Oh yeah baby. Let’s go.
Consider it a blessing.
Your cracking me up.
I use to drink the kool-aid here and the day I almost broke even was when they announced the U.S. patent. Stock closed around 1.17. The very next day they issued a price offering I believe was at .82 and it continued down from there. Biocept did a 30:1 stock split @ .16. I’m not trying to be anyone’s savior here, just saying this company only knows how to manipulate you and take your money if your long. Save your hard-earned money until they prove they have something that can make money. If you are long you’re playing poker with a stacked deck and Biocept management is the dealer. JMO so good luck if you continue to invest in Biocept.
I believe paying off debt and saving money in the long run as a good thing. If it does go down it’ll be back .
First time post here, almost doubled my position. GLTA. https://smallcappower.com/videos/videos-top-stories/organigram-holdings-cannabis-sales/
This time 5 years ago you couldn’t get a word in on this board. Oh how things have changed. Wishing something would spark this board again.
Unfortunately this company is wearing baby gloves. This company is known for a couple hypes and down she goes. I’ve witnessed a 3:1 stock split and recently a 30:1 stock split. So far I’ve only lost money here in 3 years. Only my opinion but you should spend your money elsewhere. If I didn’t remove my money when I I did I needed the pps to hit $30 for me to break even. Others before me where even higher. GLTU
Ok. Let’s see what happens. Farm bill 2018 is signed.
Well Trump, we’re waiting,.......
Congrats Surfer. Payday will come.
Jeff Sessions resigns.
Updated Nov. 7, 2018 2:49 p.m. ET
Attorney General Jeff Sessions has resigned at the request of President Trump. The move follows months of Mr. Trump expressing his displeasure with Mr. Sessions in critical tweets.
Updated Nov. 7, 2018 2:49 p.m. ET
Attorney General Jeff Sessions has resigned at the request of President Trump. The move follows months of Mr. Trump expressing his displeasure with Mr. Sessions in critical tweets.
The abrupt move ended Mr. Sessions’ tumultuous tenure as the nation’s top law-enforcement officer. Throughout, he couldn’t shake Mr. Trump’s displeasure over the special-counsel investigation into Russian interference in the 2016 election.
By Aruna Viswanatha
Updated Nov. 7, 2018 2:49 p.m. ET
Attorney General Jeff Sessions has resigned at the request of President Trump. The move follows months of Mr. Trump expressing his displeasure with Mr. Sessions in critical tweets.
I can’t copy and paste the whole presentation. Otcmarkets.com is where I went to read it. Under disclosures you’ll find the filing of their 8-k.
IMO it’s all good. Ready for the next wave into next year. GLTU
All of you interested in General Cannabis I suggest looking at the 8-k that came out today, it’s a presentation about the future of the company.
Good luck with that. I see some just not wanting it to move too fast. I’m even happier with baby steps. The faster it moves up the fast I need to start selling. If I had it my way let it stairstep all the way to heaven.
All eyes on Canada, but I still have a nice investment here. Good times are coming for all.
So what is everyone's thought about the gap from 6.63 to 7.30? Do all gaps get filled? Do the shorts pray it closes the gap or feel the squeeze coming reel soon. I'm expecting a lot of buying, don't see it dropping much if any, but then again I'm usually wrong, lol. Just glad I'm not short and will buy more any chance I get if there is a drop. Blue skies ahead longs.
Last year the 10q came out on 11/7/17. So I would think somewhere around the same time this year. If it was up to me I suggest 11/09.
Such BS but I think we are slowly making progress.
US Reschedules CBD Drug—but Not CBD Itself
Ben Adlin
September 27, 2018
(David Zalubowski/AP)
Roughly three months after the Food and Drug Administration approved the cannabis-derived pharmaceutical Epidiolex for the treatment of epilepsy disorders, the US government has officially rescheduled drugs that contain CBD—but only if they’ve already been greenlighted by the FDA.
“Any other CBD product other than Epidiolex remains a Schedule I controlled substance.”
Rusty Payne, DEA spokesperson
The rescheduling order, released Thursday and set to officially publish in the Federal Register on Friday, is far narrower than many cannabis advocates had hoped. “Specifically,” it says, “this order places FDA-approved drugs that contain CBD derived from cannabis and no more than 0.1 percent tetrahydrocannabinols in schedule V.”
In other words, rather than apply generally to all CBD-based products, the order applies to only those that have cleared FDA’s expensive and time-consuming approval process. For now, the number of pharmaceuticals covered by the order is one: Epidiolex, made by UK-based drugmaker GW Pharmaceuticals.
“What this does not do is legalize or change the status of CBD oil products,” DEA spokesperson Rusty Payne told NBC affiliate WTHR. “As of right now, any other CBD product other than Epidiolex remains a Schedule I controlled substance, so it’s still illegal under federal law.”
That statement—that other CBD products remain Schedule I substances and illegal under federal law—is a controversial one. While the DEA maintains that position, the hemp industry and medical cannabis advocates argue that CBD derived from hemp is legal—at least if the hemp was grown legally under state pilot program. (For more, see Leafly’s explainer.)
Get a clue. It’s not about just THC.
Emblems executive is mentioned in this article.
Marijuana Stocks Hope This Will Make Their Shareholders Rich
[Motley Fool]
Dan Caplinger, The Motley Fool
,Motley Fool•September 22, 2018
Investors always like winning stocks, and over the past month, the most fertile ground for big winners has come from the marijuana industry. The onset of legal sales of recreational marijuana in Canada, a growing trend toward legalization in the U.S. and elsewhere across the globe, and the rising interest in marijuana producers from established players in related consumer industries like the soft-drink and spirits industries have all helped to feed speculative fire on just how high share prices can climb.
One thing that Canada's marijuana producers realized early on was that there could be substantial benefits to establishing a trade organization to advocate for the industry's joint interests. Initially, several organizations fought on behalf of various segments of the marijuana industry. But earlier this year, several of those groups came together and combined into one new entity. This group, known as the Cannabis Council of Canada, is now working hard to push for the pot industry's best interests, both to encourage more freedom in selling cannabis products and to fight against regulations that would restrict their ability to succeed financially.
Marijuana in raw and rolled form in front of a Canadian flag.
Marijuana in raw and rolled form in front of a Canadian flag.
Image source: Getty Images.
What is the Cannabis Council of Canada?
The Cannabis Council of Canada formed in April 2018. Canopy Growth (NYSE: CGC) joined forces with two other groups, the Cannabis Canada Association and the Canadian Medical Cannabis Council, to create the new entity.
Among its initial board of directors were the following industry executives:
Avtar Dhillon, executive chair of the board of Emerald Health Therapeutics (NASDAQOTH: EMHTF)
John Fowler, CEO of Supreme Cannabis (NASDAQOTH: SPRWF)
Philippe Lucas, VP of patient research and access, Tilray (NASDAQ: TLRY)
Cam Battley, chief corporate officer, Aurora Cannabis (NASDAQOTH: ACBFF)
Alison Gordon, CEO of 48North Cannabis
Jeff Jacobson, VP of business development, Cronos Group (NASDAQ: CRON)
Darren Karasiuk, senior VP of recreational division, MedReleaf
Megan McCrae, marketing director, Aphria (NASDAQOTH: APHQF)
Jeff Ryan, VP of government and stakeholder relations, Canopy Growth
John Stewart, president of Emblem Medical division, Emblem Cannabis
Sebastien St-Louis, co-founder and CEO, HEXO
Neil Closner, former CEO, MedReleaf
These members of the Cannabis Council of Canada board appointed Allan Rewak as its executive director. Rewak had a long history with performance media industry company Pathway Group before becoming interested in the cannabis industry and working for various companies and trade groups.
What Cannabis Council of Canada wants to do
Cannabis Council of Canada has ambitious goals. As board chair Dhillon notes, "Together we will realize our shared goals of ensuring fair access for patients, successful and comprehensive legalization of adult use, building a robust legal and regulated industry, and keeping cannabis away from underage youth."
From the viewpoint of investors, Cannabis Council of Canada sees great benefits in having marijuana producers gather together to advocate for their common interests. In the words of Tilray's Philippe Lucas, "The unification of Canada's cannabis industry into one organization will streamline and strengthen our ability to advocate on behalf of our members, patients and stakeholders, and to work effectively with all levels of government."
In particular, Cannabis Council of Canada sees itself being a valuable resource for medical and recreational marijuana. As the cannabis industry evolves, the group will promote industry standards while being available to policymakers to ensure safe and responsible use of cannabis products for all uses.
Why shareholders can win
Already, Cannabis Council of Canada is making its presence known. Even as regulators at Health Canada have sought to impose an excise tax on the revenues of various companies involved in marijuana-related activities, the trade group has lobbied against the immediate imposition of the tax. Instead, it favors a wait-and-see approach that will ensure fair collection of taxes to cover the costs of regulation but without putting an undue burden on upstart cannabis producers just as recreational use in Canada begins taking off.
Where’s your proof? Canada is about to legalize mj and your already writing this company off. You shouldn’t waste our time. Move on.
Aurora Cannabis to Host Fourth Quarter 2018 Investor Conference Call on September 25, 2018
CNW Group
CNW GroupSeptember 21, 2018, 3:00 PM CDT
TSX: ACB
EDMONTON , Sept. 21, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora" or the "Company") (ACB.TO) (ACBFF) ( Frankfurt : 21P; WKN: A1C4WM), today announced that it has scheduled its conference call to discuss the results for its fourth quarter ended June 30, 2018 . The call will be hosted on Tuesday, September 25 th, 2018 at 11:00 a.m. Eastern Time by Terry Booth , Chief Executive Officer, Glen Ibbott , Chief Financial Officer, and Cam Battley , Chief Corporate Officer followed by a question and answer period.
CONFERENCE CALL DETAILS
DATE:
Tuesday, September 25th, 2018
TIME:
11:00 a.m. Eastern Time (9:00 a.m. Mountain Time)
WEBCAST:
https://bit.ly/2pnnKkA
DIAL IN NUMBER:
(647) 427-7450 or (888) 231-8191
REPLAY:
(416) 849-0833 or (855) 859-2056
Available until 12:00 midnight Eastern Time Tuesday, October 2, 2018
REFERENCE NUMBER:
2977713